Rheumatoid arthritis (RA) is a lifelong, progressive, inflammatory disease which causes damage to the cartilage and bone in the affected joints1. The disease usually starts in the wrists, hands or feet, but can affect other joints and other parts of the body2.
As it progresses, RA can lead to chronic pain and severe disability, impacting on a person’s day-to-day life and their ability to carry out everyday tasks2.
Lodotra®
Lodotra is a treatment for moderate to severe RA, in particular for those who suffer from morning stiffness.
Lodotra was first launched in Germany in April 2009, and has been approved in a further 12 countries including Austria, Belgium, Denmark, Finland, France, Luxembourg, the Netherlands, Norway, Poland, Portugal, Sweden and the United Kingdom.
Studies are planned to investigate the use of Lodotra in other indications in which cytokines play a role.
For more information, visit www.lodotra.com
References
1. Goldring S.R. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology 2003; 42 (Suppl 2); ii11 - ii16
2. National Rheumatoid Arthritis Society. Accessed at: http://www.nras.org.uk/about_rheumatoid_arthritis/what_is_ra/what_is_ra.aspx . Last accessed 26.03.10